🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

101,14 USD

Máx. histórico

123,62

846 días

Caída desde máximo

-18,18%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,34%

Cierre anterior

100,80

Rango de hoy

100,88 – 101,27

Volumen hoy

1.095.277

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,43%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,37 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 16 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/04/2023 82,80 83,76 82,13 82,67 +0,32% 1,97% 674.900
03/04/2023 82,09 82,85 81,02 82,41 -0,18% 2,23% 723.100
31/03/2023 81,25 82,71 81,25 82,56 +2,28% 1,80% 1.126.900
30/03/2023 80,14 81,66 79,64 80,72 +1,77% 2,51% 830.000
29/03/2023 80,58 80,58 78,74 79,32 -1,04% 2,28% 589.100
28/03/2023 80,91 81,61 79,48 80,15 -0,40% 2,63% 1.172.600
27/03/2023 81,13 81,95 79,84 80,47 -1,18% 2,60% 1.452.100
24/03/2023 79,33 81,75 78,55 81,43 +2,27% 4,04% 849.300
23/03/2023 81,28 83,25 79,27 79,62 -1,06% 4,89% 922.700
22/03/2023 82,33 83,55 80,44 80,47 -2,88% 3,77% 1.130.200
21/03/2023 79,98 83,82 79,85 82,86 +4,65% 4,96% 1.083.300
20/03/2023 77,84 79,45 76,58 79,18 +1,72% 3,68% 904.200
17/03/2023 78,86 80,40 77,24 77,84 -1,26% 4,01% 1.647.500
16/03/2023 72,74 78,88 72,54 78,83 +7,63% 8,72% 1.409.700
15/03/2023 71,58 73,34 71,39 73,24 +0,30% 2,72% 813.400
14/03/2023 72,72 74,09 71,66 73,02 +3,21% 3,34% 852.300
13/03/2023 69,67 71,85 68,77 70,75 -0,72% 4,42% 1.414.100
10/03/2023 72,63 74,06 70,84 71,26 -2,61% 4,43% 1.224.400
09/03/2023 75,50 76,56 72,91 73,17 -2,75% 4,83% 1.217.100
08/03/2023 74,11 76,94 73,67 75,24 +3,97% 4,41% 1.391.400
07/03/2023 73,25 73,28 71,56 72,37 -0,86% 2,35% 828.000
06/03/2023 72,49 73,76 71,19 73,00 +0,08% 3,55% 1.073.900
03/03/2023 74,00 74,04 72,14 72,94 -0,56% 2,57% 996.000
02/03/2023 72,28 73,73 72,01 73,35 +0,37% 2,38% 892.500
01/03/2023 73,96 74,36 72,71 73,08 -1,19% 2,22% 650.400
28/02/2023 72,67 74,71 72,48 73,96 +1,82% 3,06% 1.181.300
27/02/2023 73,02 75,10 72,12 72,64 +0,32% 4,08% 1.297.300
24/02/2023 69,71 73,44 69,38 72,41 +3,46% 5,82% 1.737.300
23/02/2023 70,00 71,30 67,38 69,99 +20,15% 5,60% 4.187.900
22/02/2023 58,56 59,22 57,85 58,25 -0,03% 2,34% 896.400